AIM Rule 26 Why Invest in Verona Pharma plc AIM August 2006 Admission document Financial Performance
News & Events
Capital Structure Articles of Association Share Price Information Shareholder Resources









Subscribe to our Email List






16 January 2012 Notification of Major Interest in Shares
05 January 2012 Result of General Meeting
04 January 2012 Total Voting Rights
08 December 2011 Verona Pharma successfully completes £3.25 million placing
25 November 2011 Notification of Major Interest in Shares
10 November 2011 Phase IIa RPL554 study reports positively for safety and bronchodilation in patients with mild to moderate COPD
20 September 2011 Exercise of Options
07 September 2011 VRP700 demonstrates significant anti-tussive effects in patients with chronic intractable coughing
07 September 2011 Interim Report For The Six Months Ended 30 June 2011
17 August 2011 Bronchodilation in asthmatics maintained with daily dosing of RPL554
07 June 2011 Rollover of Director Options
03 June 2011 Results of AGM
03 June 2011 AGM Statement
12 May 2011 Commencement of New Phase II Clinical Trial of RPL554 in Asthma
09 May 2011 Notice of AGM and Annual Report
21 April 2011 Appointment of WH Ireland as Joint Broker
12 April 2011 First COPD Trial with RPL554 begins in Rome
23 March 2011 Preliminary Unaudited Results for the 12 months ended 31 December 2010
01 March 2011 Total Voting Rights Update
22 February 2011 Issue of Equity
22 February 2011 Verona Pharma announces positive results for RPL554 in mild asthma at higher doses
31 January 2011 Verona Pharma applies for approval to test RPL554 in UK clinical trials
07 January 2011 Company Response to Share Price Movement
26 November 2010 Verona Pharma commences higher dose RPL554 clinical trial
26 November 2010 Proof of Concept Trials confirm RPL554 delivery possible via industry-standard inhaler devices
27 October 2010 Verona Pharma commences clinical trial of VRP700 for chronic cough
06 September 2010 Interim Report for the six months ended 30 June 2010
28 June 2010 Update on RPL554 and Cough Projects
18 June 2010 Grant of Options
03 June 2010 AGM Statement 3 June 2010
04 May 2010 2009 Annual Report and Notice of AGM
26 March 2010 Preliminary Unaudited Results for year ended 31 December 2009
20 January 2010 Notice of Interest
14 January 2010 New Year Progress Report on Verona Pharma plc
06 January 2010 Application for admission of new Ordinary Shares
24 December 2009 Result of General Meeting
11 December 2009 Director's Shareholding
08 December 2009 Posting of Circular
08 December 2009 Form of Proxy Verona Pharma PLC -- General Meeting
08 December 2009 Issue of equity to raise approximately £3 million
28 October 2009 Notice of Interest
11 September 2009 Further re: Board Appointment
11 September 2009 Board Appointment
11 September 2009 A single dose of RPL554 is safe and effective in patients with asthma
04 September 2009 Interim Results For The Six Months To 30 June 2009
04 September 2009 Interim Results For The Six Months To 30 June 2009
02 September 2009 Change in Adviser
29 May 2009 Update to Total Voting Rights
22 May 2009 Result of AGM
20 May 2009 Clinical Trial Update
11 May 2009 Issue of Equity
31 March 2009 Notification of Shareholder's Interest
25 March 2009 2008 Preliminary Unaudited Results
28 January 2009 Verona Pharma obtains regulatory approval to conduct a clinical trial of its new anti-asthma drug RPL554
09 January 2009 Notification of Shareholder's Interest
11 November 2008 Notification of Shareholder's Interest
23 September 2008 Interim Report for the six months ended 30 June 2008
09 September 2008 Verona Pharma signs to begin human clinical trials for potential anti-asthma drug
31 July 2008 Total Voting Rights
07 July 2008 Issue of Equity following Options Exercise
18 June 2008 Pharma's search for novel anti-inflammatory polysaccharides (NAIPs) advances under new agreement
28 May 2008 Issue of Equity following Options Exercise
23 May 2008 Result of AGM
19 May 2008 Planned anti-asthma and hay fever treatment passes crucial tests
14 May 2008 Issue of Equity following Options Exercise
30 April 2008 Issue of Equity following Options Exercise
02 April 2008 2007 Financial Results and AGM date
19 March 2008 Change of Registered Office
26 February 2008 Clinical trial planning underway for RPL554 as experimental inhalation toxicity studies near completion
31 January 2008 Total Voting Rights
17 January 2008 Notification of Shareholder's Interest
11 January 2008 Notification of Shareholder's Interest
08 January 2008 Notification of Shareholder's Interest
07 January 2008 Result of General Meeting and Director's Shareholdings
31 December 2007 Total Voting Shares in Company
17 December 2007 Proposed Placing and Notice of General Meeting
10 December 2007 Issue of Equity
13 November 2007 AIM-quoted Verona Pharma Seeks Drug Treatment for Coughing
06 November 2007 AIM-Quoted Verona Pharma Progresses Anti-Asthma Drug Studies
04 October 2007 Verona Pharma Launches Important Regulatory Studies for its Planned New Anti-asthma Drug
10 September 2007 Interim Report for the Six Months Ended 30 June 2007
16 August 2007 Holding(s) in Company
01 August 2007 Verona Pharma plc Notification of Website Address
04 July 2007 Verona Pharma plc Result of AGM
02 July 2007 Director Shareholding
25 June 2007 Director Shareholding
29 May 2007 Verona Pharma Annual Report (Year Ended 31 December 2006)
29 May 2007 Verona Pharma plc Commences Pre-Clinical Studies of its Lead Compound RPL554
09 May 2007 Verona Pharma Appoints WH Ireland as Nominated Adviser and Broker
26 April 2007 Preliminary Results for year ended 31 December 2006
20 March 2007 Material Transfer Agreement with HepMim Biosciences
05 February 2007 Change of Director Shareholding
22 January 2007 Verona Pharma Engages Onyx Scientific to Manufacture RPL554 for Preclinical (Toxicology) and Clinical Studies
15 December 2006 Total Voting Rights and Share Capital
15 December 2006 Update on NAIPs Programme
27 November 2006 Verona Pharma plc Advances RPL554 Drug Development Project for Treatment of Respiratory Diseases
16 November 2006 Verona Pharma signs Material Transfer Agreement with Glycomar for NAIPs programme
09 November 2006 Change of Director Shareholding
09 November 2006 Change of Notifiable Interest
02 October 2006 Change of Company Secretary and Registered Office
 

Home      Company Information      Products      AIM Rule 26      News Releases      Contact      For Staff


©2006 Verona Pharma Plc All Rights Reserved. | Disclaimer